Taiwan’s Taiex index rises 0.5% to 24,610.85 at open

Taiwan’s Taiex index rises 0.5% to 24,610.85 at open

Taiwan's Taiex index opened at 24,610.85 on September 2, 2025, marking a 0.5% increase from the previous day's close. This upward movement was driven by a variety of factors, including the strong performance of individual stocks and broader market sentiment.

One of the key contributors to the index's rise was BeiGene (ONC.US), which experienced a significant increase in its stock price, surging over 9% to close at $334.20. This notable performance comes on the heels of the company's strong financial results reported for the first half of 2025. According to Zhitong Finance, BeiGene's total revenue for the period reached 17.518 billion yuan, representing a year-on-year increase of 46.03%. The company's product revenue, which totaled 17.36 billion yuan, also saw a substantial growth of 45.8%. Notably, BeiGene recorded a net profit of 450 million yuan, marking its first profit since the beginning of the year [1]. Historical backtesting of ONC.US (BeiGene) shows that when the stock beats earnings expectations, it has historically delivered strong short-term returns. Specifically, the 3-day win rate stands at 75.00%, the 10-day win rate at 65.00%, and the 30-day win rate at 60.00%. The maximum return observed during the backtest period was 15.92%, with the highest return occurring on day 42 post-earnings.

The growth in product revenue was primarily driven by the increased sales of self-developed products such as Brukinsa (zanubrutinib capsules) and Tislelizumab (antibody), as well as licensed products from Amgen. Among these, zanubrutinib has stood out, securing the top position in both the U.S. and global BTK inhibitor markets. In the first half of 2025, global sales of zanubrutinib reached 12.527 billion yuan, a year-on-year increase of 56.2%. In the U.S. market, sales of zanubrutinib amounted to 8.958 billion yuan, with a year-on-year growth of 51.7%. The product's rapid adoption among patients and physicians in the United States is attributed to its superior clinical characteristics [1].

Meanwhile, Taiwan's Taiex index rose by 0.6% to 24,235.27 at the open on the same day, reflecting broader market sentiment [2].

References:
[1] https://news.futunn.com/en/post/61555960/us-stock-market-update-beigene-oncus-surges-over-9
[2] https://news.futunn.com/en/post/61555960/taiwan-stock-market-update-taiex-index-rises-06